AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01640470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assistive Technology Provision and Tune-Up Intervention
Description: The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist.
Study NCT01640470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Customary Care
Description: Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
Study NCT02735577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
Study NCT01695252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEMOS
Description: Patient informed clinical outcomes supervision
Study NCT01332630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I.
Study NCT01332630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
Study NCT01332630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl
Description: 12.5-25 mg intravenous (IV) push 30-60 minutes prior
Study NCT01332630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: As H2 blocker 1mg/kg IV 30-60 minutes prior
Study NCT03339583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral therapy
Description: program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off.
Study NCT00044291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hormone therapy
Study NCT03339583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
Study NCT00678431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol with Glucose, and Malate
Description: Dietary supplement delivered in grape juice
Study NCT00678431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid placebo
Study NCT03704675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: Administered orally
Study NCT00706953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib; pegylated liposomal doxorubicin
Description: 1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
Study NCT04021979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Powder Ensure
Description: Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.
Study NCT04021979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5L PEG
Description: Low volume PEG
Study NCT04021979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-controlled diet
Description: Self-controlled low residue diet.
Study NCT04021979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG
Description: Normal volume of PEG
Study NCT00522405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: * Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization
Study NCT02738203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal 2% Lidocaine
Description: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
Study NCT02738203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Surgical Lubricant Jelly
Description: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
Study NCT01483547 — intervention group
Intervention type: DEVICE
Intervention: Bispectral Index (BIS Vista, Covidien)
Description: BIS values at LOC, PI, ROC.
Study NCT03241927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Day 1 of each 3 week cycle
Study NCT05870605 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.
Study NCT02913053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
Study NCT02913053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic exercise
Description: Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
Study NCT02928276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RheumaKit: Prediction of the response to anti-TNFs DMARDs
Study NCT03056300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
Description: Powered Vascular Stapler used on vessels
Study NCT00044291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hormone therapy
Study NCT00044291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Study NCT00044291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Study NCT03934372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
Study NCT03356392 — intervention group
Intervention type: OTHER
Intervention: telephone call d90
Description: telephone call on day 90 to assess the primary outcome (mRs d90)
Study NCT00044291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antiestrogen therapy
Study NCT04512989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assesment using MOCA test
Description: Cognitive assesment using MOCA test
Study NCT02960412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: 10mg lasix given intraoperatively
Study NCT02960412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline given intraoperatively as placebo
Study NCT02932436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10 mg per os daily for 12 weeks
Study NCT02932436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
Study NCT03768193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep serratus anterior plane block
Description: Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
Study NCT03768193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgically-placed paravertebral block
Description: Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
Study NCT01735604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20-CAR vector-transduced autologous T cells
Description: anti-CD20-CAR vector-transduced autologous T cells
Study NCT01735604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetically engineered lymphocyte therapy
Description: genetically engineered lymphocyte therapy
Study NCT01718483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 50 or 70 mg administered orally, once-daily for up to 12 weeks
Study NCT01718483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once-daily, orally, for up to 12 weeks
Study NCT03049501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiving condition
Description: The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
Study NCT03049501 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition condition
Description: The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
Study NCT00927875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, starting dose 30 mg, once daily, continuous
Study NCT00927875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
Study NCT00927875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
Study NCT03367000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceprolac
Description: The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
Study NCT03367000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary counseling (DC)
Description: Received standard dietary counseling at baseline and month 6.
Study NCT04353726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight management
Description: During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
Study NCT00717145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: one risedronate 20 mg DR tablet
Study NCT00717145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 20 mg DR tablet
Study NCT00717145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 35 mg DR tablet
Study NCT00717145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 35 mg IR tablet
Study NCT03562078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Quan
Description: the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
Study NCT02067858 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Study NCT01959113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Microbiome Transplant
Study NCT01959113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Study NCT01115452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Potassium nitrate
Description: 5% potassium nitrate solution
Study NCT01115452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% Potassium nitrate
Description: 2.5% potassium nitrate solution
Study NCT01115452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water
Study NCT03915834 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Mechanical thrombectomy and/or Aspiration
Study NCT01249911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lreuteri
Description: L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
Study NCT01249911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present
Study NCT02948712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Screening Thermometer
Description: Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
Study NCT02948712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCCN Guidelines: Distress management
Description: Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
Study NCT03169569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group
Description: For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
Study NCT03169569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group
Description: All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
Study NCT01702467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2647544
Description: Capsules containing 0.5mg to 50mg of GSK2647544.
Study NCT01702467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules.
Study NCT04212767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar socket preservation with Platelet-rich fibrin
Description: The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
Study NCT02432885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: up to 20mg bid
Study NCT02776839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile sensing
Study NCT01283152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)
Description: If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
Study NCT01283152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lactulose
Description: If randomized to this arm, subjects will receive 10-30 grams per standard of care
Study NCT00822653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calf Muscle Pump Stimulation
Description: Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
Study NCT00673959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drop FID 111421
Description: Lubricant Eye Drop FID 111421 1 drop each eye one time
Study NCT00673959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drop
Description: Optive Lubricant Eye Drop 1 drop each eye one time
Study NCT03620058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART22-65s cells
Description: Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
Study NCT03620058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19 Cells
Description: Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
Study NCT00119574 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collaborative Chronic Illness Model
Study NCT04406415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days
Study NCT04406415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered three times daily for up to 5 days
Study NCT00937963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm DAG Oil
Description: Use of Palm DAG Oil to replace palm oil traditionally used in foods
Study NCT01943487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral
Study NCT01943487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil
Description: Oral
Study NCT00528424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
Study NCT03529500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Caries detection - dmtf index
Description: Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index.